Inj tedizolid phosphate
Products billed under this code include Sivextro.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Sivextro.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Sivextro | Merck Sharp & Dohme LLC | 67919-0040-02 | 2000 | $4,124.00 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $2.062 | −$0.019 | 1 MG | Inj tedizolid phosphate | v1, posted September 17, 2026 |
| 3Q26 | $2.081 | +$0.117 | 1 MG | Inj tedizolid phosphate | v1, posted September 15, 2026 |
| 2Q26 | $1.964 | $0.00 | 1 MG | Inj tedizolid phosphate | v1, posted September 15, 2026 |
| 1Q26 | $1.964 | $0.00 | 1 MG | Inj tedizolid phosphate | v1, posted September 15, 2026 |
| 4Q25 | $1.964 | +$0.051 | 1 MG | Inj tedizolid phosphate | v1, posted September 8, 2026 |
| 3Q25 | $1.913 | +$0.112 | 1 MG | Inj tedizolid phosphate | v1, posted March 10, 2026 |
| 2Q25 | $1.801 | −$0.007 | 1 MG | Inj tedizolid phosphate | v1, posted March 10, 2026 |
| 1Q25 | $1.808 | −$0.001 | 1 MG | Inj tedizolid phosphate | v1, posted December 19, 2025 |
| 4Q24 | $1.809 | $0.00 | 1 MG | Inj tedizolid phosphate | v1, posted June 11, 2025 |
| 3Q24 | $1.809 | −$0.006 | 1 MG | Inj tedizolid phosphate | v1, posted June 11, 2025 |
| 2Q24 | $1.815 | +$0.034 | 1 MG | Inj tedizolid phosphate | v1, posted March 11, 2025 |
| 1Q24 | $1.781 | +$0.041 | 1 MG | Inj tedizolid phosphate | v1, posted December 19, 2024 |
| 4Q23 | $1.74 | +$0.031 | 1 MG | Inj tedizolid phosphate | v1, posted October 10, 2024 |
| 3Q23 | $1.709 | +$0.053 | 1 MG | Inj tedizolid phosphate | v1, posted June 5, 2024 |
| 2Q23 | $1.656 | −$0.087 | 1 MG | Inj tedizolid phosphate | v1, posted February 23, 2024 |
| 1Q23 | $1.743 | −$0.001 | 1 MG | Inj tedizolid phosphate | v1, posted December 6, 2023 |
| 4Q22 | $1.744 | $0.00 | 1 MG | Inj tedizolid phosphate | v1, posted June 22, 2023 |
| 3Q22 | $1.744 | +$0.083 | 1 MG | Inj tedizolid phosphate | v1, posted June 9, 2023 |
| 2Q22 | $1.661 | $0.00 | 1 MG | Inj tedizolid phosphate | v1, posted December 14, 2022 |
| 1Q22 | $1.661 | +$0.063 | 1 MG | Inj tedizolid phosphate | v1, posted June 8, 2022 |
| 4Q21 | $1.598 | +$0.014 | 1 MG | Inj tedizolid phosphate | v1, posted June 2, 2022 |
| 3Q21 | $1.584 | −$0.001 | 1 MG | Inj tedizolid phosphate | v1, posted June 2, 2022 |
| 2Q21 | $1.585 | −$0.002 | 1 MG | Inj tedizolid phosphate | v1, posted March 1, 2022 |
| 1Q21 | $1.587 | – | 1 MG | Inj tedizolid phosphate | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.